

FORM-PTO-1390 Rev 10-96)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 001560-381
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>			U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) Unassigned <b>09/530260</b>
INTERNATIONAL APPLICATION NO. PCT/JP99/04653	INTERNATIONAL FILING DATE 27 August 1999	PRIORITY DATE CLAIMED 28 August 1998	
TITLE OF INVENTION PROCESS FOR PRODUCING ARACHIDONIC ACID-CONTAINING LIPID AND DIHOMO- $\gamma$ -LINOLENIC ACID-CONTAINING LIPID			
APPLICANT(S) FOR DO/EO/US Kengo AKIMOTO, Kenichi HIGASHIYAMA and Sakayu SHIMIZU			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1). 4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An unexecuted oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <b>Items 11. to 16. below concern other document(s) or information included:</b> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: 1. Certificate of Deposit Form Pursuant to the Budapest Treaty for SAM 0219 (FERM BP-1239); and 2. Certificate of Deposit Form Pursuant to the Budapest Treaty for SAM 2153 (FERM BP-6794).			

U.S. APPLICATION NO. (If known, see 37 CFR 1.50) <b>Unassigned</b>		<b>09/530260</b>		INTERNATIONAL APPLICATION NO. PCT/JP99/04653	ATTORNEY'S DOCKET NUMBER 001560-381
---	--	------------------	--	---	--

17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS	PTO USE ONLY
<b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b> Search Report has been prepared by the EPO or JPO ..... \$840.00 (970) International preliminary examination fee paid to USPTO (37 CFR 1.482) ..... \$670.00 (956) No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ..... \$690.00 (958) Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$970.00 (960) International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) ..... \$96.00 (962)					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$ 840.00	
Surcharge of \$130.00 (154) for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).         20 <input type="checkbox"/> 30 <input type="checkbox"/>				\$ -0-	
Claims	Number Filed	Number Extra	Rate		
Total Claims	22 - 20 =	2	X \$18.00 (966)	\$ 36.00	
Independent Claims	7 - 3 =	4	X \$78.00 (964)	\$ 312.00	
Multiple dependent claim(s) (if applicable)			+ \$260.00 (968)	\$ -0-	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 1,190.00	
Reduction for 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$	
<b>SUBTOTAL =</b>				\$ 1,190.00	
Processing fee of \$130.00 (156) for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)).         20 <input type="checkbox"/> 30 <input type="checkbox"/>				\$ -0-	
<b>TOTAL NATIONAL FEE =</b>				\$ 1,190.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 (581) per property +				\$	
<b>TOTAL FEES ENCLOSED =</b>				\$ 1,190.00	
				Amount to be: refunded	\$
				charged	\$

a. ☒ A check in the amount of \$ 1,190.00 to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. 02-4800 in the amount of \$ \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this sheet is enclosed.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Ronald L. Grudziecki  
 BURNS, DOANE, SWECKER & MATHIS, L.L.P.  
 P.O. Box 1404  
 Alexandria, Virginia 22313-1404

  
 SIGNATURE  
 for Ronald L. Grudziecki  
 NAME  
24,970  
 REGISTRATION NUMBER

Filed: April 28, 2000

09/530260

526 Rec'd PCT/PTO 28 APR 2000

Patent  
Attorney's Docket No. 001560-381

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
Kengo AKIMOTO et al. )  
Application No.: Unassigned ) Group Art Unit: Unassigned  
Filed: April 27, 2000 ) Examiner: Unassigned  
For: PROCESS FOR PRODUCING )  
ARACHIDONIC ACID-CONTAINING )  
LIPID AND DIHOMO- $\gamma$ -LINOLENIC )  
ACID-CONTAINING LIPID )

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination on the merits, please amend the above-identified application as follows:

**IN THE CLAIMS:**

In claim 7, line 2, please delete "or 6".

In claim 10, line 2, please delete "or 9".

In claim 17, line 5, please delete "to 16".

In claim 18, line 6, please delete "to 16".

In claim 19, line 2, please delete "or 18".

In claim 20, line 2, please delete "or 18".

Please add new claims 21 and 22 as follows:

--21. An arachidonic acid-containing microbial lipid containing 72% by weight or more of arachidonic acid in fat per total fatty acids in said fat.

22. The arachidonic acid-containing microbial lipid according to claim 21 wherein the percentage of eicosapentaenoic acid to the total fatty acids in said lipid is 0.5% by weight or less.--

### REMARKS

Entry of the foregoing and favorable consideration of the subject application, in light of the following remarks, are respectfully requested.

By the foregoing amendment, claims 7, 10, 17, 18, 19 and 20 have been amended to delete their multiple dependencies. New claims 21 and 22 have also been added.

Support for these new claims can be found throughout the originally filed application. No new matter has been added by the foregoing amendment.


In the event that there are any questions relating to this Preliminary Amendment, or the application in general, it would be appreciated if the Examiner would telephone the

Application Serial No. Unassigned  
Attorney's Docket No. 001560-381

undersigned attorney concerning such questions so that prosecution of this application may  
be expedited.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:   
Susan M. Dadio  
Registration No. 40,373

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: April 28, 2000

## DESCRIPTION

PROCESS FOR PRODUCING ARACHIDONIC ACID-CONTAINING LIPIDS  
AND DIHOMO- $\gamma$ -LINOLENIC ACID-CONTAINING LIPIDS

5

## Field of the Invention

The present invention relates to a process for producing lipids containing arachidonic acid or a process for producing lipids containing dihomo- $\gamma$ -linolenic acid by fermentation using a mutant in which  $\omega$ 3 unsaturation activity is decreased or deleted.

10

## Background Art

There are reports that arachidonic acid, as is docosahexaenoic acid, contained in breast milk and plays a role in the infant's development ("Advances in Polyunsaturated Fatty Acid Research," Elsevier Science Publishers, 1993, pp. 261-264) and reports on the importance of arachidonic acid in the development of fetus's height and brain (Proc. Natl. Acad. Sci. U.S.A., 90, 1073-1077 (1993), Lancet, 344, 1319-1322 (1994)), and accordingly there are moves to supplement infant formula with arachidonic acid and docosahexaenoic acid that represent major differences in the fatty acid composition between breast milk and infant formula.

15

The FAO/WHO has issued a recommendation that the intake of arachidonic acid and docosahexaenoic acid be 60 mg/kg/day and 40 mg/kg/day, respectively, for premature infants and the intake of arachidonic acid and docosahexaenoic acid be 40 mg/kg/day and 20 mg/kg/day, respectively, for mature infants.

20

As methods of obtaining these fatty acids in large amount, there are conventionally known production methods that utilize microorganisms. For example, a method utilizing a microorganism belonging to the genus Mortierella has been proposed that permits the production

25

30

35

of arachidonic acid in a shorter culturing time, with a higher yield, and using simpler processes using an inexpensive commonly used medium (Japanese Examined Patent Publication (Kokoku) No. 7-34752).

5           However, the percentage of arachidonic acid in the total fatty acids is not satisfactory with these conventional production methods. Thus, when lipids containing arachidonic acid are to be added to foods, the highest possible content of arachidonic acid is preferred  
10       since it can minimize the amount of undesirable substances added and therefore it is also desirable in terms of quality and cost. It is also desirable when arachidonic acid ethyl esters are to be isolated and purified, since the highest possible content of  
15       arachidonic acid providing highly purified products with simple procedures and at low cost.

          As methods of enhancing the percentage of arachidonic acid in lipids relative to the total fatty acids, there are many methods known in the art. For  
20       example, by culturing Mortierella alpina at 28°C in a normally aeration and agitation culture followed by culturing for further 6 days under the condition of complete glucose depletion, the percentage of arachidonic acid has successfully been raised to 67.4% (Appl.  
25       Microbial. Biotechnol. 31, 11-6 (1989)). This method, however, takes advantage of the fact that microorganisms in a starved state effect  $\beta$ -oxidation of fatty acids of triglyceride with a low degree of saturation to convert them to energy.

30           Therefore, there are actually no changes in the total amount of arachidonic acid, and due to the reduction of fatty acids with a low degree of saturation only the relative percentage of arachidonic acid is enhanced. Thus, it does not mean that the amount of  
35       produced triglycerides containing a high percentage of arachidonic acid is increased, but on the contrary it appears that the percentage of triglycerides is also

decreased as a result of  $\beta$ -oxidation.

It is known that at a temperature lower than the optimum growth temperature, microorganisms capable of producing arachidonic acid generally try to adapt to low-  
5 temperature environments by enhancing the degree of unsaturation of unsaturated fatty acids so as to maintain fluidity and the functions of the cell membrane, and thereby the activity of  $\Delta 6$  desaturase and  $\Delta 5$  desaturase become enhanced so that fatty acids having a high degree  
10 of unsaturation such as arachidonic acid are produced in greater amounts. Culturing at a low temperature is therefore desirable to enhance the content of arachidonic acid.

In a method utilizing the above property,  
15 Mortierella alpina was cultured in an aeration and agitation culture at 20°C for 16 days in which the percentage of arachidonic acid was successfully enhanced to 71.2% ("Industrial Applications of Single Cell Oils," American Oil Chemists' Society Champaign, 1992, pp. 52-  
20 60). It is known, however, that since this method requires a long time for culturing, it is not only unsuitable for industrial production but at the low temperature a part of arachidonic acid that was produced is converted to eicosapentaenoic acid by a  $\omega 3$  desaturase  
25 (Biochem. Biophys. Res. Commun., 150, 335-341 (1988)) that acts at low temperatures thereby reducing the percentage of arachidonic acid and increasing the percentage of eicosapentaenoic acid in the total fatty acids.

For example, when filamentous fungus of the genus  
30 Mortierella is cultured at 12°C for 7 weeks,  $\omega 3$  desaturase is activated and the percentage of EPA to the total fatty acids reaches 2 to 20% (J. Am. Oil Chem. Soc., 65, 1455-1459 (1988)) and accordingly the  
35 percentage of arachidonic acid decreases. In contrast, by using strains wherein  $\omega 3$  desaturase is decreased or



is lacking, the percentage of arachidonic acid to the total fatty acids in the lipid can be enhanced to 50% or more, and when mutation is repeated it can be enhanced to 70% or more and the percentage of EPA can be kept at 0.5% or less.

Little eicosapentaenoic acid is contained in breast milk, and recent studies have even shown that it is detrimental to the development of babies of premature infants ("Advances in Polyunsaturated Fatty Acid Research," Elsevier Science Publishers, 1993, pp. 261-264). Thus, there is a strong need for the development of a method that can produce lipids containing a high percentage of arachidonic acid and containing little or no eicosapentaenoic acid using an inexpensive commonly used medium, a simple process, and on a large scale.

On the other hand, dihomo- $\gamma$ -linolenic acid is converted to arachidonic acid by a  $\Delta 5$  desaturase irrespective of the culture temperature. As a method of producing dihomo- $\gamma$ -linolenic acid on a large scale by a fermentation at low cost, there is a known method of culturing by adding a substance that inhibits the activity of  $\Delta 5$  desaturase such as sesamin, episesamin, sesaminol, episesaminol, and curcumin to the medium, or a method of culturing using a mutant strain of a microorganism capable of producing arachidonic acid in which mutation has been induced so that  $\Delta 5$  desaturase activity is decreased or deleted (Japanese Unexamined Patent Publication (Kokai) No. 1-243992, Japanese Unexamined Patent Publication (Kokai) No. 3-72892, Japanese Unexamined Patent Publication (Kokai) No. 3-49688, and Japanese Unexamined Patent Publication (Kokai) No. 5-91887).

In this case also, however, culturing at a temperature lower than the optimum growth temperature such as 12°C in an attempt to enhance the dihomo- $\gamma$ -

linolenic acid content would result in the activation of the above-mentioned  $\omega$ 3 desaturase so that concern arises that a part of dihomo- $\gamma$ -linolenic acid may be converted to 8, 11, 14, 17-eicosatetraenoic acid and thereby the percentage of dihomo- $\gamma$ -linolenic acid may decrease and that of 8, 11, 14, 17-eicosatetraenoic acid may increase. Thus, there is a strong need for the development of a method that can produce lipids containing a high percentage of dihomo- $\gamma$ -linolenic acid using an inexpensive commonly used medium, a simple process, and on a large scale.

#### Disclosure of the Invention

Thus, the present invention is intended to provide a process for producing arachidonic acid-containing lipids containing a high percentage of arachidonic acid and containing little or no eicosapentaenoic acid using an inexpensive conventionally-used medium, a simple process, and on a large scale, and a process for producing lipids containing a high percentage of dihomo- $\gamma$ -linolenic acid and containing little or no eicosapentaenoic acid or 8, 11, 14, 17-eicosatetraenoic acid using an inexpensive conventionally-used medium, a simple process, and on a large scale.

After extensive research in order to attain the above objectives, the inventors of the present invention have found a microorganism in which  $\omega$ 3 desaturase activity is decreased or deleted and which is obtained by the mutagenesis of a microorganism capable of producing arachidonic acid, and thereby have completed the present invention.

Thus, the present invention is intended to provide a process for producing lipids containing arachidonic acid comprising the steps of culturing a microorganism wherein  $\omega$ 3 desaturase activity has been decreased or is lacking

at a temperature lower than the optimum growth temperature from the start of culturing or after culturing at the optimum growth temperature, said microorganism being obtained by the mutagenesis of a  
5 microorganism capable of producing arachidonic acid and belonging to the genus Mortierella, the genus Conidiobolus, the genus Pythium, the genus Phytophthora, the genus Penicillium, the genus Cladosporium, the genus Mucor, the genus Fusarium, the genus Aspergillus, the  
10 genus Rhodotorula, the genus Entomophthora, the genus Echinosporangium or the genus Saprolegnia; and then recovering lipids containing arachidonic acid from the culture.

Furthermore, the present invention is intended to  
15 provide a process for producing lipids containing arachidonic acid comprising the steps of culturing a microorganism wherein  $\omega 3$  desaturase activity has been decreased or is lacking at a temperature lower than  $20^{\circ}\text{C}$  from the start of culturing or after culturing at  $20$  to  
20  $40^{\circ}\text{C}$ , said, microorganism being obtained by the mutagenesis of a microorganism belonging to the subgenus Mortierella; and then

recovering lipids containing arachidonic acid from the culture.

25 The present invention is also intended to provide a process for producing lipids containing dihomog $\gamma$ -linolenic acid comprising the steps of

culturing a microorganism wherein  $\omega 3$   
desaturase activity has been decreased or is lacking at a  
30 temperature lower than the optimum growth temperature from the start of culturing or after culturing at the optimum growth temperature, said microorganism being obtained by the mutagenesis of a microorganism that is capable of producing arachidonic acid in which  
35 microorganism  $\Delta 5$  desaturase activity has been decreased or is lacking, and that belongs to the genus Mortierella,

the genus Conidiobolus, the genus Pythium, the genus  
Phytophthora, the genus Penicillium, the genus  
Cladosporium, the genus Mucor, the genus Fusarium, the  
5 Aspergillus, the genus Rhodotorula, the genus  
Entomophthora, the genus Echinosporangium or the genus  
Saprolegnia; and then

recovering lipids containing dihomog- $\gamma$ -linolenic  
acid from the culture.

Furthermore, the present invention is intended to  
10 provide a process for producing lipids containing dihomog-  
 $\gamma$ -linolenic acid comprising the steps of

culturing a microorganism wherein  $\omega 3$   
desaturase activity has been decreased or is lacking at a  
temperature lower than 20°C from the start of culturing  
15 or after culturing at 20 to 40°C, said microorganism  
being obtained by the mutagenesis of a microorganism in  
which  $\Delta 5$  desaturase activity has decreased or is  
lacking, which had been obtained by the mutagenesis of a  
microorganism belonging to subgenus Mortierella; and then

20 recovering lipids containing dihomog- $\gamma$ -linolenic  
acid from the culture.

#### Embodiment for Carrying out the Invention

In accordance with the present invention, as  
25 microorganisms that are subjected to mutagenesis, there  
can be mentioned microorganisms belonging to the genus  
Mortierella, the genus Conidiobolus, the genus Pythium,  
the genus Phytophthora, the genus Penicillium, the genus  
Cladosporium, the genus Mucor, the genus Fusarium, the  
30 genus Aspergillus, the genus Rhodotorula, the genus  
Entomophthora, the genus Echinosporangium and the genus  
Saprolegnia, and more preferably microorganisms belonging  
to the genus Mortierella, the genus Conidiobolus, the  
genus Pythium, the genus Entomophthora, the genus  
35 Echinosporangium and the genus Saprolegnia that have  $\Delta 6$

desaturase and  $\Delta 5$  desaturase and that can produce fatty acids up to arachidonic acid in the fatty acid biosynthetic pathway.

More specifically, there can be mentioned Pythium insidiosum ATCC28251 as a microorganism belonging to the genus Pythium; Echinosporangium transversalis ATCC16960 (NRRL3116) and ATCC18036 (NRRL5525) as a microorganism belonging to the genus Echinosporangium; Saprolegnia ferax CBS534.67, Saprolegnia lapponica CBS284.38, Saprolegnia litoralis CBS535.67, Saprolegnia moniligera CBS558.67, and Saprolegnia turfosa CBS313.82 and the like as a microorganism belonging to the genus Saprolegnia.

Specifically, in accordance with the present invention, microorganisms belonging to the genus Mortierella subgenus Mortierella that have a high ability of producing arachidonic acid are preferred. As microorganism belonging to the genus Mortierella subgenus Mortierella of the present invention, there can be mentioned Mortierella elongata, Mortierella exigua, Mortierella hygrophila, Mortierella alpina, Mortierella parvispora, Mortierella beljakovae, Mortierella globalpina, Mortierella epigama, Mortierella kuhlmanii, Mortierella acrotona, Mortierella zychae, Mortierella rishikesha, Mortierella minutissima, Mortierella bainieri, Mortierella schmuckeri, and the like, and specifically there can be mentioned strains Mortierella elongata IFO8570, Mortierella exigua IFO8571, Mortierella hygrophila IFO5941, Mortierella alpina IFO8568, ATCC16266, ATCC32221, ATCC42430, CBS219.35, CBS224.37, CBS250.53, CBS343.66, CBS527.72, CBS529.72, CBS608.70, and CBS754.68, and the like.

These strains are all available without limitations from the Institute for Fermentation Osaka (IFO), Japan, and American Type Culture Collection (ATCC) in the U.S.A., and Centrralbureau voor Schimmelcultures (CBS). It is also possible to use Mortierella elongata SAM0219 (FERM P-8703) (FERM BP-1239) that is a microbial strain

our research group has isolated from the soil.

In accordance with the present invention, microorganisms that are subjected to mutagenesis are not limited to those wild type strains described above but preferably include mutants or recombinants of the above microorganisms (wild type strains) belonging to the genus Mortierella subgenus Mortierella, in other words those that have been deliberately designed to have a higher content of arachidonic acid or dihomo- $\gamma$ -linolenic acid in lipids, or a higher content of total lipid than those produced by the original wild type strains, when they are cultured in the presence of the same substrate.

Further included are those microorganisms that were designed to produce unsaturated fatty acids at an amount equal to that produced by the wild type strains by efficiently using substrates having excellent cost effectiveness. For example, as a mutant strain in which  $\Delta 12$  desaturase activity is lacking and  $\Delta 6$  desaturase activity has been enhanced, there can be mentioned Mortierella alpina SAM2086 (FERM BP-6032), and as a mutant strain lacking  $\Delta 5$  desaturase activity that was artificially induced to enhance the productivity of dihomo- $\gamma$ -linolenic acid, there can be mentioned Mortierella alpina SAM1860 (FERM BP-3589).

In accordance with the present invention, by subjecting mutant strains of the present invention in which  $\omega 3$  desaturase has been decreased to mutagenesis, it is also possible to obtain mutant strains in which  $\omega 3$  desaturase activity has been further decreased or is lacking.

$\omega 3$  desaturase activity as used herein refers to an action of inserting a double bond in between the third and the fourth carbons from the methyl group of a fatty acid, and microorganisms in which  $\omega 3$  desaturase activity has been decreased or is lacking can be easily evaluated

for the decrease or lack of  $\omega$ 3 desaturase activity thereof.

Specifically, for the production of lipids containing arachidonic acid, it can be evaluated by the percentage of eicosapentaenoic acid in the total fatty acids in the microbial cells after a mutant that was obtained by the mutagenesis of the parent strain is cultured at a temperature lower than the optimum growth temperature, for example a temperature lower than 20°C. Thus, when the percentages of eicosapentaenoic acid in the parent strain and the mutant strain under culturing at a low temperature are compared and the percentage of eicosapentaenoic acid of the parent strain is set at 1, then if the percentage of the mutant strain is lower than 1, the activity is judged to be decreased, while if it is 0, the activity is judged to be lacking.

For the production of lipids containing dihomo- $\gamma$ -linolenic acid also, it can be evaluated by the percentage of 8, 11, 14, 17-eicosatetraenoic acid in the total fatty acids in the microbial cells after a mutant that was obtained by the mutagenesis of the parent strain (for example, a parent strain in which  $\Delta$ 5 desaturase activity has been decreased or lacked) was cultured at a temperature lower than the optimum growth temperature, for example a temperature lower than 20°C. Thus, when the percentages of 8, 11, 14, 17-eicosatetraenoic acid in the parent strain and the mutant strain under culturing at a low temperature are compared and the percentage of 8, 11, 14, 17-eicosatetraenoic acid of the parent strain is set at 1, then if the percentage of the mutant strain is lower than 1, the activity is judged to be decreased, while if it is 0, the activity is judged to be lacking.

As microorganisms for use in the process of producing dihomo- $\gamma$ -linolenic acid of the present invention, mutant strains in which  $\omega$ 3 desaturase

activity has been decreased or is lacking, that are  
obtained by the mutagenesis of microorganisms capable of  
producing arachidonic acid can be used, and more  
preferably mutant strains in which further  $\Delta 5$  desaturase  
5 activity has been decreased or is lacking, are used. In  
order to obtain mutant strains in which  $\omega 3$  desaturase  
activity has been decreased or is lacking and  $\Delta 5$   
desaturase activity also has been decreased or is  
lacking, a mutant strain obtained according to the  
10 present invention in which  $\omega 3$  desaturase activity has  
been decreased or lacked is further subjected to  
mutagenesis and thereby mutant strains in which  $\Delta 5$   
desaturase activity has also been decreased or lacked are  
selected. Alternatively, they are also obtained by  
15 subjecting strains in which  $\Delta 5$  desaturase activity has  
been already decreased or is lacking to mutagenesis so as  
to decrease or delete  $\omega 3$  desaturase activity.

Mutation treatment according to the present  
invention can be conducted by conventional mutagenesis:  
20 for example effecting irradiation treatment (X ray, gamma  
ray, neutron beams, heavy ions), ultra violet  
irradiation, high temperature treatment and the like to  
induce mutation; and by suspending microorganisms in a  
suitable buffer, to which a mutagen is added followed by  
25 incubating for a given time, which is diluted  
appropriately and inoculated on an agar medium to obtain  
colonies of mutant strains.

As mutagens, alkylating agents such as nitrogen  
mustard, methyl methane sulfonate (MMS), and N-methyl-N-  
30 nitro-N-nitrosoguanidine (NTG), base analogs such as 5-  
bromouracil, antibiotics such as mitomycin C, base  
synthetic inhibitors such as 6-mercaptopurine, dyes such  
as proflavine (other derivatives), certain carcinogens  
such as 4-nitroquinoline-N-oxide, and other compounds  
35 such as manganese chloride and formaldehyde, and the like



may be mentioned. Microorganisms used may be live cells (mycelia etc.) or spores.

As mutant strains of the present invention, for example, Mortierella alpina SAM2153 (FERM P-15767) (FERM BP-6794) wherein  $\omega 3$  desaturase activity has been  
5 extremely decreased that was induced by the present inventors from Mortierella alpina IFO8568 capable of producing arachidonic acid can be used, but it is not limiting said strain, and all other mutant strains that  
10 exhibit the ratio of an activity of smaller than 1 relative to eicosapentaenoic acid of the parent strain cultured under a low-temperature condition set as 1.

In order to culture the microbial strains for use in the present invention, spores, mycelia, or a preculture  
15 that has been previously cultured are inoculated to liquid media or solid media and are cultured. In the case of liquid media, carbon sources include, but not limited to, any of glucose, fructose, xylose, saccharose, maltose, soluble starch, molasses, glycerol, mannitol and  
20 the like that are commonly used. As nitrogen sources, in addition to natural nitrogen sources such as peptone, yeast extract, malt extract, meat extract, casamino acid, corn steep liquor, soy flour, defatted soybean meal and cottonseed meal, defined organic nitrogen sources such as  
25 urea and inorganic nitrogen sources such as sodium nitrate, ammonium nitrate, and ammonium sulfate can be used. For large scale industrial production of fatty acids or lipids containing them, liquid media are preferably used.

30 When desired, inorganic salts such as phosphates, magnesium sulfate, iron sulfate, and copper sulfate, and vitamins can also be used as trace nutrients. The concentrations of these medium components are not limited as long as they do not adversely affect microbial growth.  
35 Generally, from a practical viewpoint, carbon sources are in the range of 0.1 to 40% by weight and preferably 1 to 25% by weight, nitrogen sources are in the range of 0.01

to 10% by weight and preferably 0.1 to 10% by weight, and more preferably the initial amount added of carbon sources is 1 to 5% by weight, and that of nitrogen sources is 0.1 to 6% by weight and, during culturing, carbon sources and nitrogen sources, and more preferably only carbon sources, are fed.

The mutant strains of the present invention may be cultured at a temperature lower than the optimum growth temperature from the start of the culturing, or after culturing at the optimum growth temperature they may be cultured at a temperature lower than the optimum growth temperature. Though the optimum growth temperature as used herein may vary depending on the microorganism used, it is preferably 20 to 40°C and preferably 20 to 30°C, and a temperature lower than the optimum growth temperature is a temperature lower than 25°C, preferably a temperature lower than 20°C, and more preferably a temperature lower than 20°C and higher than 5°C. By means of the temperature control described above, the accumulation of lipids in the cells can be enhanced.

When culturing is effected at a temperature lower than the optimum growth temperature, culturing is conducted for 2 to 20 days, preferably 2 to 14 days. When culturing is conducted at the optimum growth temperature prior to culturing at a temperature lower than the optimum growth temperature, culturing is conducted for 1 to 6 days and preferably 1 to 4 days at the optimum growth temperature, and 2 to 14 days and preferably 2 to 10 days at a temperature lower than the optimum growth temperature.

pH of the medium is 4 to 10 and preferably 6 to 9, and aeration and agitation culture, shaking culture, or stationary culture is conducted.

When cultured in a solid culture, bran, chaff, rice bran or the like to which 50 to 100% by weight of water relative to the weight of the solid has been added is used, and cultured at the above temperature for 3 to 14

days. In this case, nitrogen sources, inorganic salts, and trace nutrients may be added as desired.

Furthermore, in accordance with the present invention, a substrate for biosynthesis for arachidonic acid or dihomo- $\gamma$ -linolenic acid may be added to a medium to facilitate the accumulation of arachidonic acid or dihomo- $\gamma$ -linolenic acid. Examples of substrates for biosynthesis include hydrocarbons such as tetradecane, hexadecane, and octadecane, fatty acids such as tetradecanoic acid, hexadecanoic acid, and octadecanoic acid or salts (e.g. sodium salts and potassium salts) or esters thereof, or lipids containing fatty acids as components (e.g. olive oil, coconut oil, and palm oil).

Arachidonic acid or dihomo- $\gamma$ -linolenic acid can be more effectively accumulated by culturing with the addition of said omega 6 unsaturated fatty acid that is precursor of arachidonic acid or dihomo- $\gamma$ -linolenic acid among the fatty acids. As the omega 6 unsaturated fatty acids, there can be mentioned linoleic acid,  $\gamma$ -linolenic acid, dihomo- $\gamma$ -linolenic acid, and the like, and as lipids containing said fatty acids as components there can be mentioned safflower oil, soybean oil, corn oil, cottonseed oil, Bio- $\gamma$ ( $\gamma$ -linolenic acid-containing triglyceride), and the like.

The total amount of the substrate added is 0.001 to 10% by weight and preferably 0.5 to 10% by weight relative to the medium. These substrates may be added either before or immediately after inoculating the producer microorganism, or after the start of culturing, or they may be added at both time points. The addition after the start of culturing may be once, or more than once on an intermittent basis. Alternatively, they may be added continuously. These substrates may be added as the sole carbon source for culturing.

By culturing as described above, lipids containing

arachidonic acid or dihomo- $\gamma$ -linolenic acid can be formed and accumulated in large quantities in the cells. When liquid medium is used, arachidonic acid or dihomo- $\gamma$ -linolenic acid can be harvested from the cultured cells as described below.

After culturing, cultured cells may be obtained from the culture by conventionally used means of separating a solid and a liquid such as centrifugation, filtration and the like. The cells are extensively washed with water, and preferably dried. Drying can be effected by lyophilization, air drying, and the like. Dried cells are preferably extracted with an organic solvent under a stream of nitrogen. As organic solvents, an ether, hexane, methanol, ethanol, chloroform, dichloromethane, petroleum ether, and the like can be used, and satisfactory results can also be obtained by alternate extraction with methanol and petroleum ether, or by extraction with a single layer solvent of chloroform-methanol-water. Evaporation of organic solvent from the extract under reduced pressure yields lipids containing arachidonic acid or dihomo- $\gamma$ -linolenic acid.

Instead of the above-mentioned methods, wet cells may be used for extraction. In cases like this, solvents miscible with water such as methanol and ethanol, or mixed solvents miscible with water comprising these and water and/or other solvents may be used. The other procedures are similar to those described above.

In the lipids obtained as described above, various fatty acids are contained as components of lipid compounds, for example fat. They can be directly separated, but preferably they are separated as esters with a lower alcohol, such as  $\gamma$ -linolenic acid methyl, dihomo- $\gamma$ -linolenic acid methyl, arachidonic acid methyl, and the like.

By converting into these esters, they can be readily

separated from other lipid components, and can be readily separated from other fatty acids such as palmitic acid and oleic acid (these are also esterified at the same time as arachidonic acid or dihomo- $\gamma$ -linolenic acid is esterified) that are formed in the culture. For example, in order to obtain a methyl ester of arachidonic acid or dihomo- $\gamma$ -linolenic acid, the above extracted lipids are preferably treated with dry methanol-hydrochloric acid 5-10%,  $\text{BF}_3$ -methanol 10-15%, and the like at room temperature for 1-24 hours.

In order to recover arachidonic acid or dihomo- $\gamma$ -linolenic acid from the above treated solution, extraction is preferably effected with such organic solvents as hexane, ether, ethyl acetate, and the like. The extract is then dried with anhydrous sodium sulfate and the organic solvents are preferably evaporated under reduced pressure to obtain a mixture predominantly composed of fatty acid esters. This mixture contains, in addition to the desired arachidonic acid or dihomo- $\gamma$ -linolenic acid, fatty acid methyl esters such as palmitic acid methyl ester, stearic acid methyl ester, and oleic acid methyl ester. In order to isolate methyl ester of arachidonic acid or dihomo- $\gamma$ -linolenic acid from mixtures of these fatty acid methyl esters, column chromatography, low temperature crystallization, urea inclusion, liquid-liquid countercurrent extraction can be used either singly or in combination.

In order to obtain arachidonic acid or dihomo- $\gamma$ -linolenic acid from these methyl esters of arachidonic acid or dihomo- $\gamma$ -linolenic acid, they are hydrolyzed in an alkali followed by extraction with an organic solvent such as ether and ethyl acetate.

Furthermore, in order to obtain arachidonic acid or dihomo- $\gamma$ -linolenic acid without via methyl esters thereof, the above extract is decomposed with an alkali

(e.g. 2 to 3 hours with 5% aqueous solution of sodium hydroxide), and then the decomposed material is subjected to extraction and purification according to the methods conventionally used for the extraction and purification of fatty acids.

The present invention will now be explained in more details with reference to specific examples.

#### Examples

##### 10        Example 1.

15        Mortierella alpina IFO8568 was inoculated into a large slant bottle containing 300 ml of Czapek agar medium (0.2%  $\text{NaNO}_3$ , 0.1%  $\text{K}_2\text{HPO}_4$ , 0.05%  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 0.05%  $\text{KCl}$ , 0.001%  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ , 3% sucrose, 2% agar, pH 6.0), and was cultured at 28°C for 2 weeks. After culturing, 50 ml of sterile water to which had been added 2 drops of Tween80 was added to the large slant bottle, which was shaken sufficiently, and then filtered with 4 ply gauze. This procedure was repeated twice, and the filtrate was

20        centrifuged at 8000 x g for 10 minutes. Spores thus obtained were suspended into Tris/maleate buffer solution (pH 7.5) to  $1 \times 10^6$  /ml to prepare a spore solution.

To 1.0 ml of the spore solution thus obtained, 0.5 ml of 100 mM Tris/maleate buffer solution (pH 7.5) was

25        added, and 500  $\mu\text{g}$  of the NTG solution (N-methyl-N'-nitro-N-nitrosoguanidine 5 mg/deionized water 1 ml) was added, which was subjected to mutagenesis by incubating at 28°C for 15 minutes. After adding 3 ml of 10%  $\text{Na}_2\text{S}_2\text{O}_3$ , the reaction mixture was centrifuged at 5500 x g for 10

30        minutes, and the precipitate (spores subjected to mutagenesis) was washed with 3 ml of sterile water and centrifuged at 5500 x g for 10 minutes, to which 2 ml of sterile water was added to prepare a NTG-treated spore suspension.

35        The NTG-treated spore suspension was diluted to about  $10^{-3}$  to  $10^{-4}$  and then plated on a GY agar plate (1%

glucose, 0.5% yeast extract, 0.05% Triton X-100, 1.5% agar, pH 6.0). After incubating at 28°C, developed colonies were randomly picked up, and were cultured at 28°C until growth can be seen, and after the growth was observed, the culture was stored.

The stored colonies that were picked up were cultured on a GY agar plate at 28°C for 2 days and at 12°C for 2 days, and then were punched out together with the agar prior to drying at 100°C. The dried cells obtained were placed into a screw capped test tube (16.5 mm  $\phi$ ), to which 1 ml of methylene chloride and 2 ml of dry methanol-hydrochloric acid (10%) were added and were treated at 50°C for 3 hours to methylesterify them. Four ml of n-hexane and 1 ml of water were added thereto, and extracted twice. After the solvent of the extract was evaporated using a centrifuge evaporator (40°C, 1 hour), the fatty acid methyl ester obtained was analyzed by capillary gas chromatography. After screening, Mortierella alpina SAM2153 (FERM P-15767) (FERM BP-6794) that does not produce eicosapentaenoic acid at a low temperature culture was obtained.

Example 2.

To a GY agar plate (1% glucose, 0.5% yeast extract, 0.05% Triton X-100, 1.5% agar, pH 6.0), Mortierella alpina IF08568 and Mortierella alpina SAM2153 (FERM P-15767) (FERM BP-6794) obtained in Example 1 were separately inoculated and were subjected to stationary culture. The culture temperature comprised the following 6 conditions:

1. 28°C (2 days), 12°C (2 days)
2. 28°C (4 days)
3. 12°C (6 days)
4. 28°C (4 days), 12°C (3 days)
5. 28°C (7 days)
6. 12°C (7 days)

After culturing, methyl esterification was conducted as in Example 1, and the fatty acid methyl ester thus

obtained was analyzed by capillary gas chromatography. The results are shown in Table 1.



Table 1. Comparison of fatty acid composition of *Mortierella alpina* IFO8568 and SAM2153

Culture condition (Days)		Strain	Fatty acid composition (%)									
			16:0	18:0	18:1 $\omega$ 9	18:2 $\omega$ 6	18:3 $\omega$ 6	DGLA	Ara	EPA	24:0	Others
2	2	IFO 8568	16.67	11.79	19.34	5.98	3.71	4.60	25.61	1.11	2.90	8.29
2	2	SAM 2153	15.30	12.89	16.17	6.52	4.91	5.61	28.97	0	2.85	6.78
4	0	IFO 8568	16.04	12.28	15.78	6.76	3.89	3.56	29.66	0	3.38	8.65
4	0	SAM 2153	18.63	12.27	17.19	8.37	4.36	4.49	24.59	0	3.25	6.85
0	6	IFO 8568	12.77	11.27	13.14	5.43	4.50	6.43	33.89	3.02	2.09	7.46
0	6	SAM 2153	12.65	12.31	11.61	5.90	4.84	7.08	37.02	0	1.89	6.70
4	3	IFO 8568	12.36	8.06	14.63	6.78	4.76	4.20	39.58	0	3.27	6.36
4	3	SAM 2153	11.57	7.98	11.12	6.55	4.76	5.47	43.01	0	2.99	6.55
7	0	IFO 8568	10.85	7.43	11.99	7.02	4.66	4.18	42.46	0	4.64	6.77
7	0	SAM 2153	12.96	8.64	13.06	8.47	4.47	4.12	39.36	0	3.30	5.62
0	7	IFO 8568	12.48	8.16	14.94	6.43	5.10	7.82	37.18	3.31	0.57	4.01
0	7	SAM 2153	10.42	9.66	8.63	5.62	4.64	7.08	47.28	0	1.65	5.02

16:0, palmitic acid; 18:0, stearic acid; 18:1 $\omega$ 9, oleic acid; 18:2 $\omega$ 6, linoleic acid; 18:3 $\omega$ 6,  $\gamma$ -linolenic acid;

DGLA, dihomogamma-linolenic acid; Ara, arachidonic acid; EPA, eicosapentaenoic acid; 24:0, tetracosanoic acid

The parent strain IF08568, when cultured at 12°C, produced eicosapentaenoic acid, and its ratio increased in proportion with the culturing time at 12°C, whereas the mutant strain Mortierella alpina SAM2153 (FERM P-15767) (FERM BP-6794) did not produce eicosapentaenoic acid at all even by culturing for a long time at 12°C, revealing that it is a mutant strain in which the activity of  $\omega$ 3 desaturase (enzymes that convert arachidonic acid to eicosapentaenoic acid) is lacking or extremely decreased. Also, since it was not capable of converting arachidonic acid to eicosapentaenoic acid, it was found that the content of arachidonic acid could be efficiently enhanced by culturing at a low temperature because arachidonic acid that otherwise would have been converted to eicosapentaenoic acid was accumulated by culturing at a low temperature.

Example 3.

Two ml of a medium (pH 6.0) containing 4% glucose and 1% yeast extract was placed in a 10 ml Erlenmeyer flask and was sterilized at 120°C for 20 minutes. One platinum loopful each of Mortierella alpina IF08568 and Mortierella alpina SAM2153 (FERM P-15767) (FERM BP-6794) obtained in Example 1 were inoculated on the medium, and were cultured under shaking using a reciprocating shaker (150 rpm) at 12°C for 7 days, or at 12°C for 10 days. The results are shown in Table 2. It was confirmed in the liquid culture also that no eicosapentaenoic acid was produced, even by culturing at 12°C, resulting in an enhanced ratio and an increased amount of arachidonic acid produced.

**Table 2** Comparison of fatty acid composition of and the amount of arachidonic acid produced by *Mortierella alpina* IFO8568 and SAM2153

Culture condition Temp. Days	Strain	Degree of growth (g/l)	Amount of Ara produced (g/l)	Fatty acid composition (%)									
				16:0	18:0	18:1 $\omega$ 9	18:2 $\omega$ 6	18:3 $\omega$ 6	DGLA	Ara	EPA	24:0	Others
12°C 7	IFO 8568	9.48	0.28	12.92	8.14	19.17	7.79	6.75	6.84	28.21	3.41	1.02	5.75
	SAM 2153	10.52	0.48	11.47	11.65	12.30	6.14	6.93	9.58	36.12	0	1.65	4.16
12°C 10	IFO 8568	11.50	0.72	13.42	7.98	19.80	5.78	5.57	7.17	30.73	3.50	1.12	4.93
	SAM 2153	12.88	1.41	8.71	11.85	7.75	3.95	5.79	8.51	48.22	0	2.03	3.19

16:0, palmitic acid; 18:0, stearic acid; 18:1 $\omega$ 9, oleic acid; 18:2 $\omega$ 6, linoleic acid; 18:3 $\omega$ 6,  $\gamma$ -linolenic acid;

DGLA, dihomogamma-linolenic acid; Ara, arachidonic acid; EPA, eicosapentaenoic acid; 24:0, tetracosanoic acid

Example 4.

To 2 ml of a medium (pH 6.0) containing 4% glucose and 1% yeast extract, substrates for arachidonic acid biosynthesis or lipids containing them shown in Table 3 were each added at 0.5%, and the mixture was placed in a 10 ml Erlenmeyer flask and was sterilized at 120°C for 20 minutes. One platinum loopful of Mortierella alpina SAM2153 (FERM P-15767) (FERM BP-6794) obtained in Example 1 was inoculated on the medium, and was cultured under shaking using a reciprocating shaker (150 rpm) at 12°C for 10 days. The results are shown in Table 3.

Table 3

Additive	Arachidonic acid		
	Content (%)	Amount produced	
		(g/l)	(mg/g)
No addition	48.22	1.41	109.2
Octadecane	49.23	1.46	111.2
Sodium oleate	50.10	1.56	119.3
Sodium linoleate	51.30	1.63	124.3
Sodium linolenate	52.71	1.65	123.5
Methyl oleate	52.92	1.68	127.1
Methyl linoleate	53.20	1.73	128.4
Methyl linolenate	53.25	1.74	128.6
Soybean oil	54.06	1.81	129.0
Corn oil	53.76	1.81	131.4
Cottonseed oil	54.88	1.84	130.9
Safflower oil	56.64	2.05	143.7

Example 5.

Five liters of a medium (pH 6.0) containing 2% glucose, 1.5% soy flour protein, 0.3%  $\text{KH}_2\text{PO}_4$ , 0.05%  $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ , 0.1%  $\text{Na}_2\text{SO}_4$ , and 0.1% soybean oil was placed in a 10 L jar fermentor and was sterilized at 120°C for 30 minutes. Mortierella alpina SAM2153 (FERM P-15767) (FERM BP-6794) obtained in Example 1 was inoculated and was subjected to an aeration and agitation culture at an aeration rate of 1 vvm for 10 days. The culture temperature was 20°C at the start of culturing, and from day 3 it was gradually decreased to 12°C. Only on day 1, was 1% glucose added.

From day 2, 12 ml of the culture was sampled out, was methylesterified, and the fatty acid methyl esters obtained were analyzed by gas chromatography. Figures 1a, b, c, and d each show changes in the amount (g/l) of arachidonic acid produced, the ratio (%) of arachidonic acid to the total fatty acids, the degree of growth (g/l), and glucose concentrations (%) in the medium. Culturing at a low temperature in a 10 L jar fermentor was confirmed and surprisingly the ratio of arachidonic acid to the total fatty acids reached as high as 56.4% on day 10 of culturing. Analysis of lipid fractions in the intracellular lipids on day 10 of culturing revealed that triacylglycerol was 85.8%, free fatty acids 2.1%, diacylglycerol 0.5%, phosphatidyl ethanolamine 3.8%, phosphatidyl choline 3.9%, phosphatidyl serine 2.0%, and phosphatidic acid 1.9%.

Example 6.

Five liters of a medium (pH 6.0) containing 2% glucose, 1.5% soy flour, 0.3%  $\text{KH}_2\text{PO}_4$ , 0.05%  $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ , 0.05%  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ , 0.1%  $\text{Na}_2\text{SO}_4$ , and 0.1% soybean oil was placed in a 10 L jar fermentor and was sterilized at 120°C for 30 minutes.

On the other hand, Mortierella alpina IF08568 as a parent strain in a similar manner to Example 1, was subjected to mutation treatment again to obtain Mortierella alpina SAM2239, a strain in which  $\omega 3$  desaturase activity was decreased.

This SAM2239 was inoculated and was subjected to an aeration and agitation culture at an aeration rate of 1 vvm for 12 days. The culture temperature was 24°C at the start of culturing, and from day 3 it was gradually decreased to 12°C. On day 1, 2, and 3, 1% glucose was added. On day 12, the final day of culturing, sampling was carried out, and the fatty acid methyl esters obtained were analyzed by gas chromatography. The results indicated that the ratio of arachidonic acid to

the total fatty acids reached as high as 75.1% and the amount produced thereof was 4.1 g/l.

Reference to the microorganisms deposited under the Patent Cooperation Treaty, Rule 13-2, and the name of the

5 Depository Authority

Depository Authority:

Name: the National Institute of Bioscience and Human  
Technology, Agency of Industrial Science and  
Technology

10 Address: 1-3, Higashi 1-chome, Tsukuba city, Ibaraki  
pref., Japan

Microorganism (1)

Name: Mortierella elongata SAM0219

Accession number: FERM BP-1239

15 Deposition Date: March 19, 1986

Microorganism (2)

Name: Mortierella alpina SAM2153

Accession number: FERM BP-6794

Deposition Date: August 5, 1996

CLAIMS

1. A process for producing lipids containing arachidonic acid comprising the steps of

5 culturing a microorganism in which  $\omega$ 3 desaturase activity has been decreased or is lacking at a temperature lower than the optimum growth temperature from the start of culturing or after culturing at the optimum growth temperature, said microorganism being obtained by mutagenesis of a microorganism capable of

10 producing arachidonic acid and belonging to the genus Mortierella, the genus Conidiobolus, the genus Pythium, the genus Phytophthora, the genus Penicillium, the genus Cladosporium, the genus Mucor, the genus Fusarium, the genus Aspergillus, the genus Rhodotorula, the genus

15 Entomophthora, the genus Echinosporangium or the genus Saprolegnia; and then

recovering lipids containing arachidonic acid from the culture.

2. The process for producing lipids containing arachidonic acid according to claim 1 comprising

20 culturing said mutant strain in a medium containing hydrocarbons, fatty acids, fatty acid esters, fatty acid salts, or lipids containing them as components; or adding to the culture in which said mutant strain is being

25 cultured hydrocarbons, fatty acids, fatty acid esters, fatty acid salts, or lipids containing them as components, and then further culturing.

3. A process for producing lipids containing arachidonic acid comprising the steps of

30 culturing a microorganism in which  $\omega$ 3 desaturase activity has been decreased or is lacking at a temperature lower than 20°C from the start of culturing or after culturing at 20 to 40°C, said microorganism being obtained by the mutagenesis of a microorganism

35 belonging to the subgenus Mortierella; and then

recovering lipids containing arachidonic

acid from the culture.

4. The method of producing lipids containing arachidonic acid according to claim 3 comprising culturing said mutant strain in a medium containing hydrocarbons, fatty acids, fatty acid esters, fatty acid salts, or lipids containing them as components; or adding to the culture in which said mutant strain is being cultured hydrocarbons, fatty acids, fatty acid esters, fatty acid salts, or lipids containing them as components, and then further culturing.

5. A method of producing lipids containing dihomog-linolenic acid comprising the steps of

culturing a microorganism in which  $\omega 3$  desaturase activity has been decreased or is lacking at a temperature lower than the optimum growth temperature from the start of culturing or after culturing at the optimum growth temperature, said microorganism being obtained by the mutagenesis of a microorganism capable of producing arachidonic acid and belonging to the genus Mortierella, the genus Conidiobolus, the genus Pythium, the genus Phytophthora, the genus Penicillium, the genus Cladosporium, the genus Mucor, the genus Fusarium, the genus Aspergillus, the genus Rhodotorula, the genus Entomophthora, the genus Echinosporangium or the genus Saprolegnia; and then

recovering lipids containing dihomog-linolenic acid from the culture.

6. The method of producing lipids containing dihomog-linolenic acid according to claim 5 wherein said mutant strain is a mutant strain in which further  $\Delta 5$  desaturase activity has been decreased or is lacking.

7. The method of producing lipids containing dihomog-linolenic acid according to claim 5 or 6 comprising culturing said mutant strain in a medium containing hydrocarbons, fatty acids, fatty acid esters,



fatty acid salts, or lipids containing them as components; or adding to the culture in which said mutant strain is being cultured hydrocarbons, fatty acids, fatty acid esters, fatty acid salts, or lipids containing them as components, and then further culturing.

8. A method of producing lipids containing dihomo- $\gamma$ -linolenic acid comprising the steps of

culturing a microorganism in which  $\omega 3$  desaturase activity has been decreased or is lacking at a temperature lower than 20°C from the start of culturing or after culturing at 20 to 40°C, said microorganism being obtained by the mutagenesis of a microorganism belonging to the subgenus Mortierella; and then

recovering lipids containing dihomo- $\gamma$ -linolenic acid from the culture.

9. The method of producing lipids containing dihomo- $\gamma$ -linolenic acid according to claim 8 wherein said mutant strain is a mutant strain in which further  $\Delta 5$  desaturase activity has been decreased or is lacking.

10. The method of producing lipids containing dihomo- $\gamma$ -linolenic acid according to claim 8 or 9 comprising culturing said mutant strain in a medium containing hydrocarbons, fatty acids, fatty acid esters, fatty acid salts, or lipids containing them as components; or adding to the culture in which said mutant strain is being cultured hydrocarbons, fatty acids, fatty acid esters, fatty acid salts, or lipids containing them as components, and then further culturing.

11. An arachidonic acid-containing microbial lipid containing 72% by weight or more of arachidonic acid to the total fatty acids in said lipid.

12. The arachidonic acid-containing microbial lipid according to claim 11 wherein the percentage of eicosapentaenoic acid to the total fatty acids in said lipid is 0.5% by weight or less.

13. A microorganism wherein  $\omega$ 3 desaturase activity has been decreased or is lacking, said microorganism being obtained by the mutagenesis of a microorganism capable of producing arachidonic acid and belonging to the genus Mortierella, the genus Conidiobolus, the genus Pythium, the genus Phytophthora, the genus Penicillium, the genus Cladosporium, the genus Mucor, the genus Fusarium, the genus Aspergillus, the genus Rhodotorula, the genus Entomophthora, the genus Echinosporangium or the genus Saprolegnia.

14. The microorganism according to claim 13 wherein  $\omega$ 3 desaturase activity has been decreased or is lacking, wherein said microorganism capable of producing arachidonic acid that is subjected to mutagenesis is a microorganism belonging to the genus Mortierella subgenus Mortierella.

15. The microorganism according to claim 14 wherein  $\omega$ 3 desaturase activity has been decreased or is lacking, wherein said microorganism, capable of producing arachidonic acid, that is subjected to mutagenesis is Mortierella alpina.

16. The microorganism according to claim 15 wherein  $\omega$ 3 desaturase activity has been decreased or is lacking, wherein said microorganism wherein  $\omega$ 3 desaturase activity has been decreased or lacked is Mortierella alpina SAM2153 (FERM BP-6794).

17. A lipid containing arachidonic acid wherein the arachidonic acid content in the total fatty acids in the lipid is 50% by weight or more, said lipid being obtained by culturing a microorganism according to any one of claims 13 to 16 in which  $\omega$ 3 desaturase activity has been decreased or is lacking.

18. A lipid containing arachidonic acid in which the arachidonic acid content in the total fatty acids in the lipid is 50% by weight or more and the

eicosapentaenoic acid content is 0.5% by weight or less, said lipid being obtained by culturing a microorganism according to any one of claims 13 to 16 in which  $\omega$ 3 desaturase activity has been decreased or is lacking.

5           19. A lipid containing arachidonic acid according to claim 17 or 18 wherein the arachidonic acid content in the total fatty acids in the lipid is 60% by weight or more.

10           20. A lipid containing arachidonic acid according to claim 17 or 18 wherein the arachidonic acid content in the total fatty acids in the lipid is 70% by weight or more.

ABSTRACT

A process for producing lipids containing arachidonic acid comprising culturing a microorganism in which  $\omega 3$  desaturase activity has been decreased or is lacking at a temperature lower than the optimum growth temperature from the start of culturing or after culturing at the optimum growth temperature, said microorganism being obtained by the mutation treatment of a microorganism capable of producing arachidonic acid and belonging to the genus Mortierella and the like; and then recovering lipids containing arachidonic acid from the culture.

## Declaration and Power of Attorney For Patent Application

## 特許出願宣言書及び委任状

## Japanese Language Declaration

## 日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

As a below named inventor, I hereby declare that:

私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者であると（下記の名称が複数の場合）信じています。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PROCESS FOR PRODUCING ARACHIDONIC  
ACID-CONTAINING LIPIDS  
AND DIHOMO- $\gamma$ -LINOLENIC  
ACID-CONTAINING LIPIDS

上記発明の明細書（下記の欄でx印がついていない場合は、本書に添付）は、

the specification of which is attached hereto unless the following box is checked:

☐ 月 日に提出され、米国出願番号または特許協定条約  
国際出願番号を \_\_\_\_\_ とし、  
(該当する場合) \_\_\_\_\_ に訂正されました。

☐ was filed on August 27, 1999  
as United States Application Number or  
PCT International Application Number  
PCT/JP99/04653 and was amended on  
\_\_\_\_\_ (if applicable).

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編第1条56項に定義されたとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration  
(日本語宣言書)

私は、米国法典第35編119条(a)-(d)項又は365条(b)項に基づき下記の、米国外の国の少なくとも一カ国を指定している特許協力条約365(a)項に基づく国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

## Prior Foreign Application(s)

外国での先行出願  
10-243583(Pat. Appln.)

(Number)  
(番号)

Japan

(Country)  
(国名)

28/August/1998

(Day/Month/Year Filed)  
(出願年月日)

Priority Not Claimed

優先権主張なし

☐

(Number)  
(番号)

(Country)  
(国名)

(Day/Month/Year Filed)  
(出願年月日)

☐

私、第35編米国法典119条(e)項に基づいて下記の米  
国特許出願規定に記載された権利をここに主張いたします。

(Application No.)  
(出願番号)

(Filing Date)  
(出願日)

(Application No.)  
(出願番号)

(Filing Date)  
(出願日)

私は、下記の米国法典第35編120条に基づいて下記の米  
国特許出願に記載された権利、又は米国を指定している特許  
協力条約365条(c)に基づき権利をここに主張します。また、  
本出願の各請求範囲の内容が米国法典第35編112条  
第1項又は特許協力条約で規定された方法で先行する米特  
許出願に開示されていない限り、その先行米特許出願提出日  
以降で本出願書の日本国内または特許協力条約国際提出日ま  
での期間中に入手された、連邦規則法典第37編1条56項  
で定義された特許資格の有無に関する重要な情報について開  
示義務があることを認識しています。

(Application No.)  
(出願番号)

(Filing Date)  
(出願日)

(Status: Patented, Pending, Abandoned)  
(現況: 特許許可済、係属中、放棄済)

(Application No.)  
(出願番号)

(Filing Date)  
(出願日)

(Status: Patented, Pending, Abandoned)  
(現況: 特許許可済、係属中、放棄済)

私は、私自身の知識に基づいて本宣言書中で私が行なう表  
明が真実であり、かつ私の入手した情報と私の信じるところ  
に基づく表明が全て真実であると信じていること、さらに故  
意になされた虚偽の表明及びそれと同等の行為は米国法典第  
18編第1001条に基づき、罰金または拘禁、もしくはそ  
の両方により処罰されること、そしてそのような故意による  
虚偽の表明を行えば、出願した、又は既に許可された特許  
の有効性が失われることを認識し、よってここに上記のごと  
く宣誓を致します。

I hereby declare that all statements made herein of my own  
knowledge are true and that all statements made on information  
and belief are believed to be true; and further that these  
statements were made with the knowledge that willful false  
statements and the like so made are punishable by fine or  
imprisonment, or both, under Section 1001 of Title 18 of the  
United States Code and that such willful false statements may  
jeopardize the validity of the application or any patent issued  
thereon.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## Japanese Language Declaration (日本語宣言書)

委任状： 私は下記の発明者として、本出願に関する一切の手続きを米特許商標局に対して遂行する弁理士または代理人として、下記の者を指名いたします。(弁理士、または代理人の氏名及び登録番号を明記のこと)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (list name and registration number)

William L. Mathis	17,337	Robert G. Mukai	28,531	William H. Benz	25,952
Peter H. Smolka	15,913	George A. Hovanec, Jr.	28,223	Peter K. Skiff	31,917
Robert S. Swecker	19,885	James A. LaBarre	28,632	Richard J. McGrath	29,195
Platon N. Mandros	22,424	E. Joseph Gess	28,510	Matthew L. Schneider	32,814
Benton S. Duffett, Jr.	22,030	R. Danny Huntington	27,903	Michael G. Savage	32,596
Joseph R. Magnone	24,239	Eric H. Weisblatt	30,505	Gerald F. Swiss	30,113
Norman H. Stepmo	22,716	James W. Peterson	26,057	Michael J. Ure	33,089
Ronald L. Grudziecki	24,970	Teresa Stanek Rea	30,427	Charles F. Wieland III	33,096
Frederick G. Michaud, Jr.	26,003	Robert E. Krebs	25,885	Bruce T. Wieder	33,815
Alan E. Kopecki	25,813	William C. Rowland	30,888	Todd R. Walters	34,040
Regis E. Slutter	26,999	T. Gene Dillahunty	25,423		
Samuel C. Miller, III	27,360	Patrick C. Keane	32,858		
Ralph L. Freeland, Jr.	16,110	Bruce J. Boggs, Jr.	32,344		

書類送付先

Send Correspondence to:

--Ronald L. Grudziecki  
BURNS, DOANE, SWECKER & MATHIS, L.L.P.  
P.O. Box 1404  
Alexandria, Virginia 22313-1404

直接電話連絡先： (名前及び電話番号)

Direct Telephone Calls to: (name and telephone number)

Ronald L. Grudziecki  
at (703) 836-6620

唯一または第一発明者名		Full name of sole or first inventor	
1-10 Kengo Akimoto		Kengo Akimoto	
発明者の署名	日付	Investor's signature	Date
		<i>Kengo Akimoto</i>	April 26, 2000
住所		Residence	
		Mishima-gun, Osaka, Japan	
国籍		Citizenship	
		Japanese	
私書箱		Post Office Address	
		1-9-5-1006, Yamazaki, Shimamoto-cho,	
		Mishima-gun, Osaka 618-0001, Japan	
第二共同発明者		Full name of second joint inventor, if any	
2-10 Kenichi Higashiyama		Kenichi Higashiyama	
第二共同発明者	日付	Second inventor's signature	Date
		<i>Kenichi Higashiyama</i>	April 26, 2000
住所		Residence	
		Mishima-gun, Osaka, Japan	
国籍		Citizenship	
		Japanese	
私書箱		Post Office Address	
		1-9-5-602, Yamazaki, Shimamoto-cho,	
		Mishima-gun, Osaka 618-0001, Japan	

(第三以降の共同発明者についても同様に記載し、署名をすること)

(Supply similar information and signature for third and subsequent joint inventors.)

第三共同発明者

Full name of third joint inventor, if any

Sakayu Shimizu

第三共同発明者

日付

Third inventor's signature

Date

April 26, 2000

住 所

Residence

Kyoto-shi, Kyoto, Japan

国 籍

Citizenship

Japanese

私書箱

Post Office Address

6-9, Tokiwayamashita-cho, Ukyo-ku, Kyoto-shi,

Kyoto 616-8212, Japan

第四共同発明者

Full name of fourth joint inventor, if any

第四共同発明者

日付

Fourth inventor's signature

Date

住 所

Residence

国 籍

Citizenship

私書箱

Post Office Address

第五共同発明者

Full name of fifth joint inventor, if any

第五共同発明者

日付

Fifth inventor's signature

Date

住 所

Residence

国 籍

Citizenship

私書箱

Post Office Address

第六共同発明者

Full name of sixth joint inventor, if any

第六共同発明者

日付

Sixth inventor's signature

Date

住 所

Residence

国 籍

Citizenship

私書箱

Post Office Address

(第七以降の共同発明者についても同様に  
記載し、署名をすること)

(Supply similar information and signature for  
seventh and subsequent joint inventors.)